Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children

Clinical Drug Investigation

Volumn 25, Issue 5, 2005, Pages 285-292

  Tolia, Vasundhara ^a   Han, Cong ^b   North, Janine D ^b   Amer, Fouad ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PEPPERMINT; PEPPERMINT FLAVOR; RANITIDINE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DISPERSIBLE TABLET; FEMALE; FIVE POINT FACIAL HEDONIC SCALE; FLAVOR; HUMAN; MALE; NORMAL HUMAN; ORALLY DISINTEGRATING TABLET; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STRAWBERRY; STRAWBERRY FLAVOR; SYRUP; TABLET DISINTEGRATION; TASTE PREFERENCE; TASTE TEST;

EID: 20444399835     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525050-00001     Document Type: Article

References (34)

1. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569-72
2. Nelson SP, Chen EH, Syniar GM, et al. Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000; 154: 150-4
3. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32 Suppl. 2: S1-S31
4. Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211-5
5. Freston JW, Chiu YL, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361-7
6. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1-5
7. Tolia V, Johnston G, Stolle J, et al. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup in children aged between 5-11 years. Pediatr Drugs 2004; 6 (2): 127-31
8. Matsui D, Lim R, Tschen T, et al. Assessment of the palatability of β-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151: 599-602
9. Matsui D, Barron A, Rieder M. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacol Ther 1996; 30: 586-8
10. Angelilli ML, Toscani M, Matsui DM, et al. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med 2000; 154: 267-70
11. Uhari M, Eskelinen L, Jokisalo J. Acceptance of antibiotic mixtures by infants and children. Eur J Clin Pharmacol 1986; 30: 503-4
12. Keast RS, Breslin PA. Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts. Pharm Res 2002; 19: 1019-26
13. Temple ME, Nahata MC. Comparative palatability of 22 liquid antacids. Aliment Pharmacol Ther 2000; 14 (4): 421-5
14. Bahal-O'Mara N, Force RW, Nahata MC. Palatability of 14 over-the-counter antacids. Am Pharm 1994; NS34 (1): 31-5
15. Marriott C. The effect of flavour on acceptability of antacid tablets. J Clin Hosp Pharm 1983; 8 (1): 69-73
16. Schneider RP, Roach AC. An antacid tasting: the relative palatability of 19 liquid antacids. South Med J 1976; 69 (10): 1312-3
17. Prodi DA, Drzyna D, Forabosco P, et al. Bitter taste study in a Sardinian genetic isolate supports the association of phenylthiocarbamide sensitivity to the TAS2R38 bitter receptor gene. Chem Senses 2004; 29 (8): 697-702
18. Kim U, Drzyna D. Genetics of individual differences in bitter taste perception: lessons from the PTC gene. Clin Genet 2005; 67 (4): 275-280
19. Zantac Product Information. GlaxoSmithKline, Research-Triangle Park, NC, USA. October 2004
20. Prevacid Product Information. TAP Pharmaceutical Products Inc., Lake Forest, IL, USA. 2004
21. Pumfrey B, Baxter G. Patient administration and acceptability of the lansoprazole oro-dispersible tablet. Presented at the 12th United European Gastroenterology Week, 25-29 September 2004, Prague, Czech Republic. Wed-G-292. Gut 2004; 53 Suppl. VI: A289
22. Freston JW, Jackson RL, Huang B, et al. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002; 62 (8): 1173-84
23. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52-62
24. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39
25. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2RA therapy. The lansoprazole maintenance study group. Am J Gastroenterol 1996; 91: 1758-65
26. Savarino V, Mela GS, Zentilin P, et al. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. Fundam Clin Pharmacol 1996; 10 (3): 304-8
27. Savarino V, Mela GS, Zentilin P, et al. Once-daily bedtime dose of roxatidine and ranitidine in acute duodenal ulcer: a combined assessment of acid inhibitory activity and healing rate. Am J Ther 1995; 2 (12): 949-53
28. 2-blockers. Nippon Rinsho 1992; 50 (1): 60-7
29. Tolia V, Fitzgerald J, Hassall E, et al. Safety of iansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S300-7
30. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S308-18
31. Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69 (6): 655-9
32. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123 (1): 148-54
33. Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149 (3): 267-71
34. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15 (9): 1397-402